Pfizer “Right-Of-Reply” Theory Reflects Interest From FDA, Firm Says
Executive Summary
Pfizer's amicus curiae brief articulating a "right-of-reply" for manufacturers reflects FDA's interest in the topic, Pfizer Senior Corporate Counsel Arnold Friede told an Institute for International Research conference on off-label use March 28 in Washington, D.C